REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Circadian Reset Protocol

Sleep Optimizationintermediate
32
Peptides

3

Avg Daily mcg

3,000

Level

intermediate

Added

May 16, 2026

Overview

The Circadian Reset Protocol is an intermediate-level sleep optimization stack engineered to restore disrupted circadian rhythms, deepen sleep architecture, and promote neurological recovery during rest. By combining DSIP, Selank, and Epithalon, this protocol addresses the three primary drivers of poor sleep: disrupted delta-wave signaling, elevated nighttime anxiety, and dysregulated melatonin production. DSIP (Delta Sleep-Inducing Peptide) at 200mcg daily is a neuropeptide that modulates sleep architecture by promoting slow-wave (stage 3-4) sleep without the sedative hangover of pharmaceutical sleep aids. DSIP works through the hypothalamic sleep-wake axis, normalizing sleep onset latency and increasing the proportion of restorative deep sleep. Research has shown DSIP to be particularly effective for individuals with stress-related insomnia and disrupted sleep-wake cycles from shift work or travel. Selank at 300mcg daily is an anxiolytic heptapeptide derived from the naturally occurring immunomodulatory peptide tuftsin. It reduces GABAergic anxiety and calms overactive evening cortisol without cognitive impairment or dependency. By quieting the hypervigilant nervous system that keeps many people awake at night, Selank creates the neurochemical conditions necessary for natural sleep onset. It also enhances BDNF expression, supporting memory consolidation during sleep. Epithalon at 5000mcg every other day restores pineal gland function and normalizes endogenous melatonin secretion. Rather than supplementing exogenous melatonin (which can downregulate natural production), Epithalon stimulates the pineal gland to produce melatonin at physiologically appropriate times, re-anchoring the circadian clock. Protocol Notes: DSIP and Selank are best administered 60-90 minutes before desired sleep onset. Epithalon can be taken in the morning or evening on alternating days. This stack is suited for professionals dealing with high-stress schedules, frequent travelers crossing time zones, shift workers, or anyone whose natural sleep rhythm has been disrupted. A typical cycle runs 30-60 days. Users often report vivid dreaming, easier morning waking, and significantly improved daytime energy within the first two weeks.

Dosing Protocol

DSIP

Every day

200 mcg

per dose

Selank

Every day

300 mcg

per dose

Epithalon

Every other day

5,000 mcg

per dose

Goals & Evidence

Evidence tier:community

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.